



IFW

1617

LD0268 US - NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Gary D. Greenblatt
Type or print name

Gary D. Greenblatt
Signature

10/11/06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1617

FRANCIS LEE, ET AL.

EXAMINER: CHONG, YONG SOO

APPLICATION NO: 10/091,061

FILED: 03/05/2002

FOR: COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR
THE TREATMENT OF PROLIFERATIVE DISORDERS.

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a Foreign Office Action in a corresponding Russian application. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).




Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Gary D. Greenblatt
Agent for Applicant
Reg. No. 47,609
Phone: 609-252-3850
Date: 10/11/06

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

PTO/SB/08A (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COMPLETE IF KNOWN

Application Number	10/091,061
Filing Date	03/05/2002
First Named Inventor	Francis Y.F. Lee
Art Unit	1614
Examiner Name	Yong Soo Chong
Attorney Docket Number	LD0268 NP

Sheet 1 of 1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Publication date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	6,162,804	12/19/00	Bilodeau et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Check box if English language translation is attached
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AB	Baselga, J. et al., "Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination with Cisplatin", J. Clin. Oncol., Vol. 18, No. 4, pgs. 904-914 (2000).	
	AC	Winkler, U. et al., "Cytokine-Release Syndrome in Patients with B-Cell Chronic Lymphocytic Leukemia...", Blood, Vol. 94, No. 7, pgs. 2217-2224 (1999).	
Examiner Signature			Date Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant